ECO Animal Health Group (LON:EAH) Share Price Crosses Below 200 Day Moving Average - Here's Why

Key Points

• Shares fell below their 200-day moving average (200‑day MA GBX 98.93), trading as low as GBX 92 and last at GBX 93.78 on volume of 65,110 shares.
• Analyst sentiment remains positive: Shore Capital reaffirmed a "buy" and the MarketBeat consensus is a Buy rating with an average price target of GBX 160.
• ECO's fundamentals show a market cap of £62.83m and P/E of 21.33, with a high debt‑to‑equity ratio of 5.97 but strong liquidity (current ratio 3.73, quick ratio 2.14) and very low volatility (beta 0.05).

Shares of ECO Animal Health Group plc (LON:EAH - Get Free Report) crossed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of GBX 98.93 and traded as low as GBX 92. ECO Animal Health Group shares last traded at GBX 93.78, with a volume of 65,110 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, Shore Capital Group restated a "buy" rating on shares of ECO Animal Health Group in a research report on Wednesday, March 11th. One research analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of GBX 160.

ECO Animal Health Group Price Performance

The company has a debt-to-equity ratio of 5.97, a current ratio of 3.73 and a quick ratio of 2.14. The stock has a market capitalization of £62.83 million, a price-to-earnings ratio of 21.33 and a beta of 0.05. The company has a 50-day simple moving average of GBX 96.85 and a two-hundred day simple moving average of GBX 98.93.

About ECO Animal Health Group

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline. Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide. Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.